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Background: Self-management models can be a very powerful resource in the health system provided they are well
tailored to a particular disease and setting. Patient outcomes have been demonstrated to improve when
self-management practices are embedded in the care of people with certain diseases. However, it remains unclear
whether self-management models and specific components of these programmes can be implemented in order to
effectively improve the care of people with diabetes and/or chronic kidney disease.
Methods/Design: Medline (including Medline in-process), Excerpta medica database (EMBASE), Cumulative Index
to Nursing and Allied Health (CINAHL) and all evidence-based medicine (EBM) will be systematically searched for
randomised controlled studies comparing self-management models with usual care in patients with diabetes or
chronic kidney disease. Two reviewers will independently assess articles for eligibility: extract data, evaluate risk of
bias and complete quality assessment of included studies. The data will be tabulated and narratively synthesised.
Meta-analyses will be performed if there is sufficient homogenous data.
Discussion: This protocol utilises rigorous methodology as well as pre-specified eligibility criteria to comprehensively
search for diabetes and kidney disease self-management models which have been compared with usual care in
randomised controlled trials. The review is likely to provide insight into the effectiveness of current models for
improving patient self-management, and this may address the key translational issue of how to integrate and
tailor these self-management practices for patients with diabetes and chronic kidney disease.
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Chronic diseases are defined as illnesses that are pro-
longed in duration, do not often resolve spontaneously
and are rarely cured completely [1]. They are the largest
cause of death globally [2]. Among these diseases are
diabetes and chronic kidney disease. The incidence and
prevalence of diabetes mellitus has soared throughout
the world, mainly due to the increase in type 2 diabetes,
which in turn is largely related to the increase in over-
weight and obesity [3, 4]. It is projected that by 2025,
there will be 380 million people with type 2 diabetes and
418 million people with impaired glucose tolerance [5].
Direct medical costs of treating diabetes and its compli-
cations during a lifetime are estimated to be $85,000 in
the United States. In this regard, diabetes presents a
huge financial challenge to the health system and the
economy at large.
Chronic kidney disease can occur as a sequela of or in-
dependent of diabetes. Worldwide, CKD affects over 200
million people [6] and diabetes contributes 30–40 % of all
end stage kidney disease (ESKD) cases [7]. In developed
countries, diabetes-related kidney damage is the leading
cause of treated end stage kidney disease accounting for
approximately 50 % of cases [8]. Given the incidence of
diabetes is increasing, a concurrent rising tide of people
with kidney disease is anticipated.
Due to the complex nature of diabetes and CKD, it is
not only important to prevent but to improve the entire
continuum of care from prevention to treatment and
self-management. Several self-management strategies
have therefore been implemented to manage illnesses
and minimise the impact on patients, families and the
health system [9]. These strategies have been organised
into models, which have produced some favourable
outcomes including improvement of the physiological
measures of disease, adherence to treatment, health
service and self-reported health measures such as
health-related quality of life [10]. However, the approach
to self-management in these various chronic disease
models has differed substantively. While some are
centred on patient education, motivational interviewing
and health coaching, others follow a much broader ap-
proach of the way the patient relates to health providers
and the community.
Given the wide array of chronic disease health care
models and self-management practices promulgated, it
is possible to apply a model which poorly fits the par-
ticular chronic disease and setting of implementation.
For example, often a “mismatch” between the needs of
the patients and health care available exists due to the
traditional acute care orientation of existing health sys-
tems [11–13]. Several studies have compared the out-
comes of usual care (for various diseases in different
settings) with one or other chronic disease health caremodels in order to identify the most effective means by
which to provide care [13–15]. However, the effective-
ness of these models in the management of people with
diabetes and CKD has not been established.
A systematic review of the evidence is required to pro-
vide insight as to the most effective self-management
models and the specific components of chronic disease
health care models that can be implemented in order to
improve the outcomes of people with diabetes and
chronic kidney disease (CKD) [16, 17].
Objectives of the systematic review
The objectives of this study are to investigate:
 The effectiveness of current diabetes and CKD
management models in improving clinical outcomes
of patients with diabetes and CKD,
 The common elements of a model of care that
improves patient outcomes for diabetes and CKD and
 The effectiveness of current models of care in
improving self-management in diabetes and CKD
patients.
Conceptual framework
As depicted in Fig. 1, a CKD/diabetes self-management
model needs to have activities or interventions which
are applied to the target population in addition to their
usual care. These activities include patient education, pa-
tient reminders, motivational interviewing, health coach-
ing, increased access to health experts and incentives.
The impact of these interventions can be classified as
short-term outcomes, intermediate outcomes and long-
term outcomes.
Short-term outcomes measure the initial impact of an
activity, for instance, improved self-efficacy. They capture
the “potential” for continued change created through ac-
tivities and their outputs. Intermediate outcomes are often
few and are seen in individuals who continue to partici-
pate in self-management activities. They are the changes
believed to be created by the project and not only impact
individuals directly participating in the project’s activities
but impact those connected to them such as families,
friends and community partners. Long-term outcomes
may be achieved after a lengthy duration (7–10 years), and
they represent the ultimate goal for the project.
Methods
Systemic review design
A systematic review and meta-analysis which adopts
methods outlined in the Cochrane Handbook for System-
atic Reviews of Interventions guidelines [18] and conforms
to the reporting guidelines of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses for Pro-
tocols (PRISMA-P) statement recommendations [19] will
Fig. 1 Programme logic model for a chronic kidney disease/diabetes self-management programme
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guided by the PICOS format.
Population/participants
Adult patients (above 18 years) with diabetes and CKD
in any healthcare setting (acute care, primary health
care, family medical practice, general medical practice,
clinics, outpatient departments, rehabilitation or com-
munity settings) in all countries.
Interventions
Chronic disease management models focusing on the
healthcare provider or the patient will be considered.
As a typical chronic disease management model has
multiple interventions, relevant interventions will be
classified into five groups [12]:
 Use of evidence-based planned care
 Reorganisation of practice systems and provider roles
 Improved patient self-management support
 Increased access to expertise
 Availability of clinical information
Relevant intervention components include [20]:
 Provider education—includes education materials or
instructions given to the healthcare provider to aid
with the management of a given chronic disease.
 Provider feedback—information given to healthcare
providers regarding the care or results of care
experienced by their patient. Provider reminders—prompts given to providers to
perform specific patient care tasks.
 Patient education—materials and instructions given
to patients to enhance the management of their
chronic disease condition.
 Patient reminders—prompts given to patients to
remind them to perform specific tasks related to the
management of their disease condition.
 Patient financial incentives—payments (direct or
indirect) to patients for achieving certain disease
management goals.
Only studies whose chronic disease management models
have included one or more of the above components will
be eligible for inclusion.Comparator
Usual or standard care must be clearly defined to be eli-
gible for inclusion in this systematic review. This may be
the chronic disease management programme that is
already in place before a new model of care is introduced.
Usual care will potentially present some challenges in this
study since this may differ depending on setting.Outcomes
Primary Clinical indicators (blood pressure, eGFR and
HbA1C): non-invasive measures of blood pressure per-
formed by an automated machine or manually by a
health practitioner will be accepted.
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to medication, diet, lifestyle changes or appointment keep-
ing. All validated adherence measurement tools will be
considered, including but not limited to direct observable
behaviour, subjective self-reports (patient-reported out-
come), objective monitoring of medication usage, object-
ive physiological/biomedical measures, health outcomes
or combined adherence measurements. Examples of some
of the validated tools are the Medication Event Monitoring
System (MEMS) [21], medication adherence report scale
(MARS-5) [22], Morisky medication taking adherence
scale (MMAS) [23] and the brief medication questionnaire
(BMQ) [24].
Self-management behaviour: self-management (SM)
can be defined as the “active management by individuals
of their treatment, symptoms and lifestyle, physical and
psychological consequences inherent with living with a
chronic condition” [25]. To achieve adequate SM skills,
individuals may require a series of SM interventions ad-
dressing their area of need. Effectiveness of SM models
will be determined by evaluation of at least two key
areas, such as, but not limited to whether people devel-
oped the skills to manage their own health and secondly,
whether this has resulted in better health. Measures of
impact of SM may include the patient activation meas-
ure (PAM) indicators such as patient knowledge, skill
and confidence for SM and prediction of a range of
behaviours including healthy behaviours, disease specific
management behaviours and consumeristic type of
behaviours [26]. The method of measurement of SM
behaviour must be reported to be eligible for inclusion
in this systematic review.
Health service utilisation: measures of the population’s
use of the health care services available to them, incorp-
orating economic indicators which are based on volume
such as number of hospitalisations and number of visits
per year. Ideally, chronic disease management models
would aim for fewer hospitalisations due to the financial
connotations associated with health service utilisation. It
is very important to note that health service utilisation
may be a long-term outcome and therefore may only be
properly ascertained by studies with a reasonably longer
follow-up period.
Health-related quality of life: only validated tools will be
considered including EuroQol 5D [27], quality of life scale
(QoLS) [28] and the kidney disease quality of life instru-
ment (KDQOL) [29].
Adverse outcomes: adverse events such as hospitalisa-
tion and deaths will be considered in this review.
Study design/setting
Randomised controlled trials: For the purpose of this
review, only randomised controlled studies and system-
atic reviews of randomised controlled studies, reportingadequate information to allow for estimation of at least
one relevant outcome of the chronic disease manage-
ment model as outlined above, will be considered.
The following publication types will be excluded: articles
reporting non-randomised studies, narrative reviews, let-
ters, editorials, commentaries, unpublished manuscripts,
dissertations, government reports, books and book chap-
ters, conference proceedings, meeting abstracts, lectures
and addresses, and consensus development statements
and guidelines.
Language: Studies published in English language will
be included.Search methods
The following electronic databases will be used to identify
relevant literature using a systematic search developed
according to the selection criteria (Additional file 1):
 Medline
 Medline in-process and other non-indexed citations
 EMBASE
 CINAHL
 All Evidence-Based Medicine (EBM) Reviews
incorporating The Cochrane Library, Cochrane
Database of Systematic Reviews (Cochrane reviews),
Database of Abstracts of Reviews of Effects (other
reviews), Cochrane Central Register of Controlled
Trials (clinical trials), Cochrane Database of
Methodology Reviews (methods reviews), The
Cochrane Methodology Register (methods studies),
Health Technology Assessment Database (technology
assessments), NHS Economic Evaluation Database
(economic evaluations) and ACP Journal Club.
We will also search the bibliographies of relevant stud-
ies identified by the search strategy for identification of
additional studies. The National Institute of Health Clin-
ical Trials Register (https://clinicaltrials.gov/) and the
Australian and New Zealand Clinical Trials Registry
(https://www.anzctr.org.au/) will also be searched.Inclusion of studies
To determine the literature to be assessed further, two
reviewers (EZ and CL) will scan the titles, abstract sections
and keywords of every record retrieved by the search strat-
egy (Fig. 2). Full articles will be retrieved for further assess-
ment if the information given suggests that the study
meets the inclusion criteria. If there is any doubt regarding
these criteria from the information given in the title and
abstract, the full article will be retrieved for clarification.
During the full text review, if the two reviewers are in
doubt about the inclusion of any particular study, there
will be an option of involving the third reviewer (MM).
Fig. 2 Prisma flow diagram showing how studies will be screened
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the kappa statistic and 95 % confidence interval.
Assessment of methodological quality
Methodological quality of the included studies will be
assessed by two reviewers (EZ and CL) using the Monash
Centre for Health Research and Implementation (MCHRI)
template for appraisal of methodological quality of a
randomised controlled trial (Additional file 2) [30]. This
template uses a descriptive component approach to assess
risk of bias as well as outline internal and external validity.
Any disagreement will be resolved by discussion with MM
to reach a consensus.
Quality of evidence
The grading technique recommended by Guyatt and
associates [28] will be used to assess the quality of the
body of evidence for each outcome of interest. The ef-
fect estimate will be assessed for direction and size of
the effect. In considering the quality of evidence for theeffect, the following five factors will be considered: in-
directness, risk of bias, imprecision, inconsistency and
publication bias.
Overall quality will be classified as high, moderate, low
and very low. Randomised controlled trials will start
with high quality rating with each consideration being
downgraded by 1 or 2 points as necessary. The final
quality score will be interpreted as shown in Table 1.Data extraction
Data will be extracted from included studies using a spe-
cially developed data extraction form according to the
selection criteria. Information will be collected on gen-
eral details (title, authors, reference/source, country, year
of publication, setting), participants (age, sex, inclusion/
exclusion criteria, withdrawals/losses to follow-up, sub-
groups), results (point estimates and measures of vari-
ability, frequency counts for dichotomous variables,
number of participants, intention-to-treat analysis) and
validity results.




High quality Very confident that the true effect lies close to the estimate of the effect and therefore further research very unlikely to change
our confidence in the estimate of effect
Moderate quality Moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility
that it is substantially different. Further research likely to have an important impact on our confidence and may change the estimate
Low quality Confident that the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. Further
research very likely to have an important impact on our confidence and is likely to change the estimate
Low Very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect
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Data will be presented in summary form and descrip-
tively, in tables or narratively for each clinical question.
Where appropriate, meta-analyses will be conducted.
Data will be summarised statistically if they are avail-
able, sufficiently similar and of sufficient quality. The
Review Manager 5.3.5 software will be used for statistical
analysis. Results will be expressed as relative risks (RR)
with 95 % confidence interval (CI) for dichotomous out-
comes and weighted mean differences (WMD) with
95 % CI for continuous outcomes. Results of clinically
and statistically homogenous trials will be pooled to pro-
vide estimates of the effectiveness of the interventions.
Clinical homogeneity will be satisfied when participants,
interventions, outcome measures and timing of outcome
measurement are considered to be similar. For trials that
are clinically heterogeneous or present insufficient infor-
mation for pooling, a descriptive analysis will be per-
formed. Statistical homogeneity will be assessed using the
I2 test where I2 values over 50 % indicate moderate to high
heterogeneity [31]. Pooled results will be analysed using a
random-effects model, assuming a degree of heterogeneity
among self-management trials being sought here. Statis-
tical significance will be set up at P ~ 0.05 for primary and
secondary outcome measures.
Subgroup analysis
Subgroup analysis will be conducted according to age,
gender and duration of intervention since these factors
may cause variations in outcomes. The duration and
type of self-management training will also be considered
carefully.
A sensitivity analysis will be done according to risk of
bias. For meta-analyses containing more than ten studies,
funnel plots will be employed in order to investigate small
study effects as well as publication bias [32]. Publication
bias will be determined where a symmetrical inverted fun-
nel plot indicates the absence of bias and an asymmetrical
funnel plot indicates the presence of bias.
Narrative A narrative synthesis will be performed using
a framework that consists of the following four elements
as highlighted by several authors [33–36]:1. Developing a preliminary synthesis of findings of
included studies.
2. Assessing the robustness of the synthesis which will
involve performing a critical reflection with special
emphasis to the methodology of the synthesis
(focusing on the limitations and their possible
impact on the results), evidence used (quality,
reliability, validity and generalizability), assumptions
made, discrepancies and uncertainties identified and
how discrepancies were dealt with, areas where the
evidence is weak or non-existent, possible areas for
future research and, finally, a discussion of the
evidence presented that will consider the “thick” and
“thin” evidence and comment on similarities and/or
differences between evidences.
3. Exploring relationships within and between studies
will be done in three ways namely;
i. Moderator variables and subgroup
analysis—study characteristics that vary between
studies or sample (subgroup) characteristics
which might help explain differences in findings
will be identified.
ii. Idea webbing and concept mapping—idea
webbing conceptualises and explores connections
among the findings reported in the review studies
and often take the form of a spider diagram.
iii.Qualitative case descriptions—descriptions of
outliers or exemplars of why particular results
were found in the outcome studies.
4. Developing a theory of how the intervention works,
why and for whom.
Discussion
Our review utilises rigorous methodology as well as
pre-specified eligibility criteria to comprehensively search
for diabetes and CKD health care models and self-
management practices which have been compared with
usual care in randomised controlled trials. The search
strategy for this review was developed in consultation with
a methodological expert (MM). Furthermore, eligibility
and risk of bias and extraction of data will be independ-
ently assessed by a team of two reviewers while a third
reviewer will be available to adjudicate discrepancies.
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lies on published data so publication bias cannot be
ruled out. We may also miss some relevant studies as we
have limited the search to publication date and English
language due to funding and time constraints.
Our review will provide insight into the effectiveness of
current chronic disease health care models for improving
patient self-management, and this may address the key
translational issue of how to integrate and tailor these self-
management practices to patients with diabetes and CKD.
If the existing models are found to be less efficient, this re-
view may flag avenues for further research.
Additional files
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critical appraisal of randomised controlled trials.
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